Prednisolone

證據等級: L5

預測適應症: 10 個

Prednisolone: From Corticosteroid Therapy to Alopecia Areata

One-Sentence Summary

Prednisolone is a synthetic glucocorticoid used broadly as an anti-inflammatory and immunosuppressive corticosteroid, with established clinical use across many autoimmune, allergic, rheumatologic, and renal conditions. The TxGNN model predicts it may be effective for Alopecia Areata, with 18 registered clinical trials and 20 publications identified for this drug-disease pair — though, as detailed below, only a subset of the trials directly test corticosteroid/prednisolone therapy in this indication.

Quick Overview

Item	Content
Original Indication	Not specified in this evidence pack (no original indication text or Canadian licence on file; prednisolone is generically a broad-spectrum corticosteroid)
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.99%
Evidence Level	L2
Canada Market Status	Not Marketed
Number of DINs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for prednisolone is not available in this evidence pack (flagged as a High-severity data gap). Based on established pharmacological knowledge, prednisolone is a synthetic glucocorticoid that binds the glucocorticoid receptor to suppress transcription of pro-inflammatory cytokines and inhibit T-lymphocyte activation and proliferation. It is a long-established, broadly used anti-inflammatory and immunosuppressive agent across many autoimmune, allergic, dermatologic, rheumatologic, and renal conditions.

Alopecia areata (AA) is a T-cell-mediated autoimmune disease in which the immune privilege of the hair follicle collapses, allowing cytotoxic T cells to attack the follicle and halt hair growth. Because prednisolone (and the closely related glucocorticoid methylprednisolone) suppresses pathogenic T-cell activity through the same mechanism it uses in other autoimmune diseases, its application to AA is mechanistically consistent rather than a novel hypothesis — systemic and pulse-dose corticosteroids have in fact been used as a standard-of-practice treatment option for severe, treatment-resistant AA for decades.

It is worth noting that prednisolone currently has 0 DINs on file and a “Not Marketed” status in Canada under this evidence pack. So while the mechanistic rationale and clinical literature are supportive, any repurposing pathway would still need to establish (or re-establish) a regulatory product pathway in Canada before clinical use could proceed.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01167946	Phase 4	Completed	42	Oral mega-pulse methylprednisolone evaluated in severe, therapy-resistant AA using higher doses and more frequent pulses than prior protocols; directly supports pulse-corticosteroid efficacy in refractory AA.
NCT01017510	N/A	Unknown	20	Compared a needle-free DERMOJET injector vs. standard syringe for intralesional steroid delivery in AA; informs local-delivery route options rather than systemic efficacy.
NCT07101471	N/A (Observational)	Completed	296	Real-world safety/effectiveness study of tofacitinib in alopecia, in which participants received it with or without adjuvant prednisolone; provides real-world context for prednisolone as an adjunct therapy.

Note: The evidence pack returned 18 trials for this drug–disease pair, but the remaining 15 (e.g., studies of BMS-986165, baricitinib, ALPN-101, VIB7734, PF-06700841, sirolimus, efavaleukin alfa, anifrolumab, LCAR-AIO, enpatoran) were Phase 2/3 trials of non-corticosteroid investigational agents in systemic lupus erythematosus, or unrelated studies (olaparib in metastatic prostate cancer; occipital nerve block for headache). These were excluded from the table as not directly relevant to prednisolone’s use in alopecia areata.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15692475	2005	RCT (placebo-controlled)	J Am Acad Dermatol	First placebo-controlled study of oral pulse prednisolone therapy in AA, establishing a randomized evidence base for pulse-corticosteroid use.
37870096	2023	Review (network meta-analysis)	Cochrane Database Syst Rev	Network meta-analysis comparing immunosuppressants, hair-growth stimulants, and contact immunotherapy for AA, situating corticosteroid pulse therapy among ranked treatment options.
30191561	2019	Review (systematic)	Australas J Dermatol	Systematic review (1946–2018 RCTs) of systemic treatments for AA, totalis and universalis; summarizes comparative efficacy evidence including systemic corticosteroids.
37992355	2023	Review	Dermatol Pract Concept	Reviews efficacy, relapse rates, side effects, and prognostic factors across different pulse-corticosteroid regimens for AA.
41243342	2025	Review	J Dermatolog Treat	Discusses durable remission with dexamethasone oral mini-pulse in severe AA when JAK inhibitors are unavailable/ineligible, reinforcing corticosteroid pulse therapy as a systemic alternative.
21572877	2009	Cohort (retrospective)	Dermatoendocrinol	Evaluated medium-dose prednisolone pulse therapy directly in AA patients; effective in early-stage disease, with notable steroid-related adverse effects.
22426909	2012	Cohort (retrospective)	Saudi Med J	Published results of an intensive oral mega-pulse methylprednisolone regimen (same protocol as NCT01167946) in severe therapy-resistant AA.
35986630	2022	Cohort (retrospective)	Dermatol Ther	Compared methylprednisolone alone vs. methylprednisolone + methotrexate in 26 patients with extensive AA.
28140540	2017	Cohort (retrospective, pediatric)	J Dtsch Dermatol Ges	Evaluated sequential high- then low-dose systemic corticosteroid therapy in severe childhood AA to balance efficacy against long-term steroid side effects.
26179196	2015	Cohort (retrospective, pediatric, long-term)	Dermatol Ther	Long-term follow-up (median 96 months) of 65 children/adolescents with severe AA treated with combined oral pulse and topical corticosteroid therapy.

Canada Market Information

Prednisolone currently has no DIN (Drug Identification Number) on file in this evidence pack — market status is listed as Not Marketed, with 0 total licences recorded. No product-level dosage form or approved-indication text is therefore available for this drug in Canada.

Safety Considerations

Please refer to the package insert for safety information.

(This evidence pack currently has a Blocking data gap for TFDA/product-label warnings and contraindications, and no drug–drug interaction records were found — 0 interactions returned.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale:

Alopecia areata has a mechanistically consistent, T-cell-mediated autoimmune pathology that pulse-dose corticosteroids (prednisolone/methylprednisolone) are already used to treat in clinical practice. This is supported by one Phase 4 trial (NCT01167946), a placebo-controlled study (PMID 15692475), multiple retrospective cohorts, and two tier-1 systematic reviews/network meta-analyses — consistent with the pack’s L2 evidence-level / S3 decision-stage classification. However, it reflects an already-established practice pattern rather than a genuinely novel repurposing signal, and a Blocking safety data gap (DG001) currently prevents completion of the S1 safety pre-assessment.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain the official product monograph/label warnings and contraindications for prednisolone to complete the safety pre-screen.
Resolve DG002 (High): obtain detailed mechanism-of-action data from DrugBank to formally document the pharmacological rationale.
Confirm the Canada regulatory pathway, since 0 DINs are currently on file (market status: Not Marketed) — determine whether reactivating an existing submission or filing a new drug application would be required.
Complete a formal drug–drug interaction (DDI) review, since the current query returned no interaction records.
For context: TxGNN also flagged idiopathic steroid-sensitive nephrotic syndrome (rank 10) at evidence level L1 with the same “Proceed with Guardrails” recommendation — a stronger-evidence signal than alopecia areata, though also reflecting an already-established use rather than a new hypothesis. Several other candidates (alopecia mucinosa, telogen effluvium, folliculitis decalvans, and various rare genetic syndromes) were rated L4–L5 with a Hold recommendation and are not pursued further at this time.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.